Dimerix

Dimerix Financial Leverage

The Financial Leverage (Equity Multiplier) of Dimerix (DXB.AX) as of Oct 11, 2026 is -3.97. In the previous year, Financial Leverage (Equity Multiplier) was 6.81 — a change of -158.26% (lower).

Financial Leverage

-3.97

YoY

-158.26%

Last updated:

Financial Leverage (Equity Multiplier) of Dimerix is 2026 -3.97 . Financial Leverage (Equity Multiplier) of Dimerix was 2025 6.81 . It decreases by -158.26% lower compared to the previous year.

The Dimerix Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.18 AUD
Jan 1, 2020
1.34 AUD
Jan 1, 2021
6.42 AUD
Jan 1, 2022
1.14 AUD
Jan 1, 2023
2.98 AUD
Jan 1, 2024
1.76 AUD
Jan 1, 2025
6.81 AUD
Jan 1, 2026
-3.97 AUD
The Dimerix Financial Leverage history
YEARFinancial LeverageYoY
-3.97-158.26%
6.81+286.33%
1.76-40.76%
2.98+160.34%
1.14-82.17%
6.42+379.13%
1.34+13.90%
1.18+10.97%
1.06-3.00%
1.09-3.02%
1.13+5.34%
1.07-98.11%
56.45—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Financial Leverage (Equity Multiplier) of Dimerix is -3.97 in 2026.

Financial Leverage (Equity Multiplier) of Dimerix changed from 6.81 to -3.97, representing a -158.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Dimerix

All Key Metrics — Dimerix